Eucrates Biomedical Acquisition Corp. Unit
EUCRU
EUCRU was delisted on the 26th of April, 2023.
17 hedge funds and large institutions have $41.2M invested in Eucrates Biomedical Acquisition Corp. Unit in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
5% less capital invested
Capital invested by funds: $43.5M → $41.2M (-$2.26M)
11% less funds holding
Funds holding: 19 → 17 (-2)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WC
Wealthspring Capital
West Harrison,
New York
|
+$86.4K |
| 2 |
SMA
Sage Mountain Advisors
Atlanta,
Georgia
|
+$26.5K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$300 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$816K |
| 2 |
SCM
Sio Capital Management
New York
|
-$513K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$11.1K |
| 4 |
Verition Fund Management
Greenwich,
Connecticut
|
-$889 |
EUCRU Hedge Fund Activity: Q3 2021 in Review
17 of the 5,728 institutional investors tracked by Wall St. Rank reported a position in Eucrates Biomedical Acquisition Corp. Unit (EUCRU) for Q3 2021, worth a combined $41.2M — down 5.2% from $43.5M a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of EUCRU and 0 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Wealthspring Capital, adding an estimated $86.4K. The largest seller was Millennium Management, exiting entirely with an estimated $816K sold.
- 17 institutional investors held Eucrates Biomedical Acquisition Corp. Unit (EUCRU) as of Q3 2021, down from 19 in Q2 2021.
- Funds reported $41.2M of Eucrates Biomedical Acquisition Corp. Unit stock for Q3 2021, down 5.2% quarter-over-quarter.
- 0 funds opened new Eucrates Biomedical Acquisition Corp. Unit positions in Q3 2021 and 2 closed out, a net change of -2 holders.
- The largest Eucrates Biomedical Acquisition Corp. Unit buyer in Q3 2021 was Wealthspring Capital, an estimated $86.4K added.
- The largest Eucrates Biomedical Acquisition Corp. Unit seller in Q3 2021 was Millennium Management, an estimated $816K sold.
Based on aggregated 13F filings for Q3 2021.